Form 4: United Therapeutics Director Rothblatt Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4 Filing
Martine Rothblatt, a director at United Therapeutics, executed stock option exercises and sales on May 23 and 24, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, a director at United Therapeutics Corp, engaged in transactions involving the company's stock on May 23 and 24, 2024.
- These transactions involved the exercise of stock options and the subsequent sale of common stock.
- The exercises were conducted at a price of $129.49 per share.
- The sales were executed at varying prices, ranging from approximately $270.92 to $277.27 per share.
- These transactions were carried out under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- The plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
- Following these transactions, Rothblatt continues to hold a significant number of shares both directly and indirectly through various trusts.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's future prospects.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of August 31, 2024, or the exhaustion of 723,869 stock options expiring on December 31, 2024.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It is common for executives and directors to utilize 10b5-1 trading plans to manage their stock holdings and avoid accusations of insider trading. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Comparison to Industry Standards
- It's difficult to compare these transactions to industry standards without knowing the specifics of Rothblatt's compensation package and overall holdings.
- However, the use of 10b5-1 plans is a common practice among executives at publicly traded companies, including those in the biotechnology and pharmaceutical sectors like Amgen, Gilead Sciences, and Johnson & Johnson, to manage their stock sales in a compliant manner.
- The size of the transactions is relatively small compared to the overall market capitalization of United Therapeutics.
Key Dates
| Date | Description |
|---|---|
| 2014-12-31 | Original grant date of stock options that expire on December 31, 2024 |
| 2023-08-04 | Date of establishment of the 10b5-1 trading plan. |
| 2024-05-23 | Date of first reported transaction (exercise and sale of stock). |
| 2024-05-24 | Date of second reported transaction (exercise and sale of stock). |
| 2024-05-28 | Date of filing of the Form 4. |
| 2024-08-31 | Potential end date of the 10b5-1 trading plan. |
| 2024-12-31 | Expiration date of the tranche of 723,869 stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.